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Abstract  
 
Myelin sheath thickness is precisely regulated and essential for rapid propagation of action potentials 
along myelinated axons. In the peripheral nervous system, extrinsic signals from the axonal protein 
neuregulin 1 type III regulate Schwann cell fate and myelination. Here we ask if modulating neuregulin 
1 type III levels in neurons would restore myelination in a model of congenital hypomyelinating 
neuropathy (CHN). Using a mouse model of CHN, we rescued the myelination defects by early 
overexpression of neuregulin 1 type III. Surprisingly, the rescue was independent from the upregulation 
of Egr2 or essential myelin genes. Rather, we observed the activation of MAPK/ERK and other myelin 
genes such as peripheral myelin protein 2 (Pmp2) and oligodendrocyte myelin glycoprotein (Omg). 
We also confirmed that the permanent activation of MAPK/ERK in Schwann cells has detrimental 
effects on myelination. Our findings demonstrate that the modulation of axon-to-glial neuregulin 1 type 
III signaling has beneficial effects and restores myelination defects during development in a model of 
CHN. 
 
Abbreviations: CHN, congenital hypomyelinating neuropathy; HA-NRG1, hemagglutinin tagged 
NRG1; Mpz/P0, myelin protein zero; NCV, nerve conduction velocity; NRG1, neuregulin 1; Omg, 
oligodendrocyte myelin glycoprotein; P30, post-natal day 30; Pmp2, peripheral myelin protein 2; 
Q215X, Gln215 stop codon nonsense mutation. 
 
Nomenclature: GENE   PROTEIN 
Human  NRG1 type III    NRG1 type III  
 
Mouse:  Nrg1 type III      NRG1 type III 
 
Transgene:  HA-Nrg1 type III HA-NRG1 type III  
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Introduction 
 
The neuregulin 1 (NRG1) family of ligands and cognate ErbB tyrosine kinase receptors 
(heterodimeric ErbB2/B3), regulate much of Schwann cell development (Birchmeier and Nave, 2008; 
Garratt et al., 2000; Lin et al., 2000; Meyer and Birchmeier, 1995; Michailov et al., 2004; Nave and 
Salzer, 2006; Riethmacher et al., 1997; Taveggia et al., 2005). NRG1 function depends on isoform and 
amount of expression (Fricker et al., 2011; Gomez-Sanchez et al., 2009; Stassart et al., 2013). In 
particular, the level of expression of the axonal membrane bound NRG1 type III is a potent instructive 
signal that determines whether a Schwann cell will form myelin, as well as its thickness (Michailov et 
al., 2004; Taveggia et al., 2005).  A series of mouse genetics experiments have elucidated the complex 
molecular network downstream of NRG1/ErbB2/ErbB3 that regulates myelination during development 
and remyelination (Fledrich et al., 2014; Pereira et al., 2012; Stassart et al., 2013). Intrinsic Schwann 
cell signals downstream of NRG1 include PI3K/AKT, MAPK/ERK and calcineurin/NFATc4, which 
are required to precisely regulate myelin gene transcription and protein synthesis required for myelin 
formation (Brinkmann et al., 2008; Grossmann et al., 2009; He et al., 2010; Kao et al., 2009; Maurel 
and Salzer, 2000; Newbern et al., 2011; Ogata et al., 2004).   
Expressed almost exclusively by myelin-forming Schwann cells, myelin protein zero (MPZ/P0) 
is the major protein in myelin of the peripheral nervous system (PNS) and is necessary for normal 
myelin structure and function (Giese et al., 1992). In addition to structural interactions with the 
membrane, the P0 cytoplasmic tail is thought to contain motifs that assemble signal complexes to 
stimulate myelin gene expression and therefore modulate myelin thickness (Giese et al., 1992; Xu et 
al., 2000). A human nonsense mutation in the Mpz gene generates a premature stop codon in the P0 
protein at glutamine 215 (P0Q215X). This truncates the P0 cytoplasmic tail and causes a severe 
congenital hypomyelinating neuropathy (CHN) in patients, characterized by weakness, hypotonia and 
areflexia from birth, associated with a severely reduced nerve conduction velocity (Mandich et al., 
1999; Warner et al., 1996). The molecular mechanisms underlying how truncation of P0 triggers 
hypomyelination are not well understood.  
 In this study, we used a mouse model of CHN with the targeted mutation of Mpz encoding the 
P0Q215X mutant protein. Mice heterozygous for Q215X (MpzQ215X/+) manifest diminished motor 
performance, and hypomyelination that recapitulates a mild Q215X human nerve pathology (Fratta et 
al., 2018). Genetic experiments suggest that the Q215X phenotype results from a combination of loss 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/386748doi: bioRxiv preprint first posted online Aug. 7, 2018; 
4  
and gain-of function. Here we find that the neuregulin axis is intact in Q215X nerves, but myelin gene 
expression is reduced. Although overexpression of the Mpz gene does not impact on the Q215X 
phenotype (Fratta et al., 2018), we reasoned that augmented activity of Nrg1 type III might compensate 
for hypomyelination in CHN by increasing myelin gene expression and myelin thickness (Michailov 
et al., 2004). To test this, we crossed Q215X mice with a transgenic mouse overexpressing HA-Nrg1 
type III in neurons (Velanac et al., 2012). We observed an improvement in myelin thickness and nerve 
conduction velocity (NCV) in Nrg1 type III:Q215X mice. Transcriptional and biochemical analyses 
identified MAPK/ERK as the likely signaling pathway responsible for rescuing Q215X defects in 
Schwann cells.   
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Results 
 
Myelin protein levels are reduced in Q215X mice 
We showed that MpzQ215X/+ mice present an hypomyelination in sciatic nerves (Fig. 1A, B), caused by 
a technical loss of function and a dose-dependent gain of abnormal function (Fratta et al., 2018). Thus, 
although the Q215X mutant allele caused a mild phenotype, the Q215X model displayed features of a 
human CHN with non-progressive hypomyelination throughout development (Fratta et al., 2018).  
To determine if the hypomyelination in MpzQ215X/+ Schwann cells is caused by a misregulation of 
myelin genes, we quantified RNA and protein levels of the major myelin genes in Q215X mutants 
during development. Both Q215X heterozygote and homozygote sciatic nerves showed a reduction of 
Pmp22 and Mag mRNA at early time points P5 and/or P10, when myelination is initiating (Fig. 1 C-
F). In addition, Q215X heterozygote and homozygote sciatic nerves had reduced levels of PMP22, 
MAG and MBP at P5 (Fig. 1 G-J and Fig. EV1). We analyzed the mRNA and protein levels for Egr2, 
a key transcriptional regulator of myelin genes, but did not find any dysregulation, suggesting that the 
underexpression of myelin genes in Q215X is independent of Egr2 (Fig. 1 F, J). These results suggest 
that the Q215X allele affect myelin protein expression and is well suited for the study of therapeutical 
approaches aiming at rescuing hypomyelination. 
 
Overexpression of NRG1 type III restores myelin thickness in Q215X mice 
NRG1 type III expressed on axons determines whether Schwann cells will form myelin, and its 
thickness, through the activation of the master myelin gene transcription factor Egr2 (Kao et al., 2009; 
Taveggia et al., 2005). Overexpressing NRG1 type III isoform in sensory and motor neurons 
significantly increases myelin thickness in the peripheral nervous system (Michailov et al., 2004; 
Velanac et al., 2012).  
 Q215X mutants present a hypomyelination with decreased myelin gene expression, likely due 
to a loss of transcriptional signals. Thus, we expect that introducing exogenous expression of HA-
NRG1 type III in a hypomyelinating context (Q215X) could activate transcription of myelin genes and 
restore myelin thickness. We bred Q215X mice with the HA-NRG1 type III hemizygous transgenic 
mouse model (Nrg1t3) that overexpresses HA-NRG1 type III under the control of the neuronal Thy1.2 
promoter (Campsall et al., 2002; Caroni, 1997).  
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 Morphological and ultrastructure analysis of Nrg1t3;Q215X sciatic nerves were performed at 
one month of age and compared to Q215X heterozygote (Q215X) littermates. First, we confirmed by 
morphologic measurements that the newly generated Q215X and Nrg1t3 mice present 
hypomyelination and hypermyelination, with respectively 0.72±0.01 and 0.53±0.02 as G ratio, as 
compared to 0.67±0.005 in wildtype littermates (Fig. 2 A-C). Second, we observed that double mutant 
animals present a dramatic recovery of myelin thickness when compared to Q215X, and return to a 
myelin thickness close to wild-type (WT) animals with a G ratio of 0.62±0.01 (Fig. 2A-C).  
 As previously described with transgenic expression of HA-NGR1 type III (Michailov et al., 
2004; Velanac et al., 2012), the increase in myelin thickness was predominantly observed in small 
caliber axons (Fig. 2C). We also observed that Nrg1t3 animals present increased internodal length as 
well as more myelinated small caliber fibers from 1 to 2 µm (Fig. EV2A-C). 
 As expected, in Q215X animals the hypomyelination observed in one-month old animals 
correlated with a reduction of nerve conduction velocities (Fig. 2D). In the Nrg1t3 mice sciatic nerve 
axons were well myelinated, and there was no alteration of nerve conduction velocity and F wave 
latency (Fig. 2D, E). The increase of myelin thickness in Nrg1t3;Q215X led to an improvement of 
nerve conduction velocities (Fig. 2D). However, the nerve conduction velocities do not return to the 
wild-type level, likely due to the pronounced effect of Nrg1 type III on small caliber fibers that 
contributes in a minor way to electrophysiological measurements of nerve conduction velocity. The F-
wave latencies were also improved in Nrg1t3;Q215X, suggesting an increase in proximal myelination 
(Fig. 2E).  
 P0 is essential for proper myelin compaction (Ding and Brunden, 1994; Kirschner and Ganser, 
1980; Lemke, 1988; Shapiro et al., 1996). To exclude that the changes in myelin thickness were due to 
a defect in compaction, we analyzed the periodicity of myelin sheath, but no difference between 
mutants and WT were found (Fig. 2F, G).  
Q215X mutant displayed early postnatal altered motor performance (Fratta et al., 2018). 
Therefore, we assessed the effect of HA-NRG1 type III on motor performance using the grid-walking 
test at P15. Unlike the first transgenic mouse model generated which developed mild tremor (Michailov 
et al., 2004), no visible tremor phenotype was described in the Nrg1t3 transgenic mouse (Velanac et 
al., 2012). However, the grid-walking test at P15 revealed motor coordination deficits (more ‘foot 
faults’ were recorded as compared to WT) in Nrg1t3 mice. This interfered with the behavioral 
investigations to assess a possible motor rescue in Nrg1t3;Q215X mice (Appendix Fig. S1).  Multiple 
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studies in human and rodents link mutations in NRG1 gene or imbalanced ErbB4/NRG1 signaling to 
schizophrenia-like behaviors accompanied by increased anxiety levels and disrupted sensorimotor 
gating, which were recently associated to an impaired synaptic plasticity (Agarwal et al., 2014; Hahn 
et al., 2006; Lee et al., 2016; Luo et al., 2014; Walther and Strik, 2012; Weickert et al., 2012).  
 
Expression of NRG1 type III is uncoupled from major myelin gene transcription and 
myelin protein expression.  
We further assessed the molecular mechanism responsible for the increase in myelin thickness and the 
functional improvements we observed. We first confirmed that the active from of NRG1 type III was 
expressed in Nrg1t3 and Nrg1t3;Q215X adult mice in spinal cord lysates (Fig. EV3A). Despite this, 
the level and activation of NRG1 type III receptors in Schwann cells, tyrosine kinase receptors ErbB2 
and ErbB3, were unchanged in the presence of transgenic expression of Nrg1t3 at P30 (Fig. EV3B). 
Next, we quantified the level of major compact (P0, PMP22, MBP) and non-compact myelin (MAG) 
proteins in one-month old nerves. Despite exogenous expression of the NRG1 type III active form, no 
significant increase in the major myelin proteins was detected (Fig. 3A and Fig. EV3C). To further 
confirm that the increase in myelin thickness in Nrg1t3 animals was independent from an increase in 
myelin gene expression, we measured P0 protein levels in the myelin sheath using immunoelectron 
microscopy. We observed a decrease of P0 density in the myelin sheath of Nrg1t3 mutants (Fig. 3B), 
corresponding to an increase in myelin area without any increase in P0 protein levels. Thus, P0 proteins 
are more diluted in the myelin of Nrg1t3 mutants. This quantification supports our biochemical results 
of unchanged level in P0 protein despite the hypermyelination (Fig. 3A and Fig. EV3C).  
 EGR2 is the key regulator of myelination, myelin protein and cholesterol/lipid biosynthesis 
gene expression (Le et al., 2005; Leblanc et al., 2005; Srinivasan et al., 2012; Topilko et al., 1994). 
Consistent with unchanged myelin gene transcription in hypermyelinated sciatic nerves of Nrg1t3 
mice, Egr2 expression was not altered in Nrg1t3 mice at one month of age (Fig EV3D-E). We also 
crossed our mice with mice expressing the luciferase reporter gene mRNA (Lucif) under the control of 
the Hsp68 promoter fused to a PMP22 enhancer with EGR2/SOX10 binding sites (Luc D hemizygotes 
(Luc D) mice, (Jones et al., 2011)). Quantification of the relative expression of Luc D in Q215X;LucD; 
Nrg1t3;Luc D and Nrg1t3;Q215X;LucD sciatic nerves at P15 indicated that EGR2 transcriptional 
activity was not affected (Fig. EV3F). These results suggest that exogenous HA-NRG1 type III 
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promotes an increase in myelin thickness independently of the most common myelin genes and the 
modulation of the master Egr2 transcription factor. 
 
The signaling pathways downstream of NRG1 type III are activated in Nrg1t3 mutant 
mice  
We next sought to determine if increased NRG1 type III signaling in Nrg1t3 mice elicits activation of 
known signaling pathways downstream of ErbB2/3 that are necessary for Schwann cell development, 
differentiation and myelination, PI3K/AKT, calcineurin/NFATc4 and MAPK/ERK (Grossmann et al., 
2009; Kao et al., 2009; Maurel and Salzer, 2000; Newbern et al., 2011; Ogata et al., 2004). These three 
signaling pathways are thought to trigger Egr2 dependent gene activation and subsequently 
myelination downstream of NRG1 type III.  
 The activity of AKT was increased in both Nrg1t3 and Nrg1t3;Q215X one-month old sciatic 
nerves (Fig. 4A) which correlates with previous in vitro and in vivo observation (La Marca et al., 2011; 
Syed et al., 2010; Taveggia et al., 2005).  In addition, we found hyperactivation of ERK1/2 pathway in 
both Nrg1t3 mutant mice (Fig. 4B), in agreement with recent findings that sustained and augmented 
MAPK/ERK signaling increases myelination (Ishii et al., 2013; Sheean et al., 2014).  
The total amount and the active form of NFATc4 were unchanged (Fig. 4C). Altogether these results 
suggest that NRG1 type III overexpression induces the activation of both PI3K/AKT and MAPK/ERK, 
independently of the transcription factor EGR2.  
 
MAPK/ERK is enhanced by the exogenous expression of axonal NRG1 type III  
While myelin thickness was increased with NRG1 type III transgene expression, EGR2 was unaltered. 
Therefore, we asked whether we could identify the transcriptomic signature of one of the canonical 
pathways downstream of NRG1 type III that could explain the increase in myelination in sciatic nerves 
of Nrg1t3 and Nrg1t3;Q215X mice.    
 We conducted a transcriptomic analysis of wildtype, Q215X, Nrg1t3 and Nrg1t3;Q215X sciatic 
nerves at 28 days of age, using mRNA next-generation sequencing. We looked for available gene 
libraries of signaling pathways downstream ErbB2/3/NRG1 type III, such as EGR2, NFATc4 and 
MAPK/ERK. We then systematically calculated the Pearson’s correlation coefficient (r) as measure of 
linear correlation on fold change expression between our subset of gene regulated downstream of 
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NRG1 type III and subset of gene known to be regulated downstream of NRG1 type III-related 
pathways.  
 We first used a list of gene regulated downstream of an hypomorphic Egr2 allele (Egr2Lo/Lo) 
expressed in mouse sciatic nerve at one month old (Le et al., 2005), that mimics a Egr2 loss of function. 
Thus, a negative correlation between Nrg1t3 and Egr2Lo/Lo mice transcriptome should reveal the 
activation of EGR2 downstream of ErbB2/3/NGR1 type III signaling pathway. The absence of 
correlation, indicated by a coefficient r = 0.27 between Erg2Lo/Lo and Nrg1t3 and r = 0.19 between 
Erg2Lo/Lo and Nrg1t3;Q215X (Fig. 5A), confirmed that the hypermyelination mediated by HA-NRG1 
type III was uncoupled from EGR2-regulated genes. 
 Second, although NFATc4 is thought to regulate Sox10 and Egr2 expression (Kao et al., 2009), 
no comprehensive analysis of NFATc4 target genes in Schwann cells has been published. Given that 
NFATc4 is a nuclear partner of SOX10 (Kao et al., 2009) and that SOX10 is a transcriptional activator 
of myelination, we used a hypergeometric-based test and data mining to first assess whether the sets of 
regulated genes from RNA sequence analysis of experimental nerves were enriched for genes identified 
by ChIP-Seq analysis of enhancers bound by SOX10. Previous studies had localized peripheral nerve 
enhancers through ChIP-seq of histone H3K27 acetylation, and Sox10-bound enhancers were 
identified (Hung et al., 2015; Lopez-Anido et al., 2015; Srinivasan et al., 2012). Sox10-bound 
enhancers were analyzed for the presence of NFAT motifs and annotated to the nearest expressed gene 
in peripheral nerve.  By dividing these putative SOX10 target genes into two categories—either with 
or without NFATc4 motifs within 50Kb up or downstream of the gene, we inferred putative NFATc4 
regulation.  This analysis showed that genes regulated in nerves from either Nrg1t3 versus WT, or 
NRg1t3:Q215X versus Q215X, were enriched specifically for SOX10 target genes with NFATc4 
motifs (Appendix Table S1). Surprisingly, those genes were significantly downregulated (Appendix 
Table S1), indicating that exogenous expression of HA-NRG1 type III activates less, or may even 
repress, NFATc4/SOX10 target genes. 
 Finally, to assess if genes known to be regulated downstream of the MAPK/ERK pathway 
correlate with those regulated downstream of ErbB2/3/NRG1 type III, we used an expression profile 
obtained from one-month old transgenic mice expressing a Schwann cell specific constitutive active 
form of the kinase MEK1 (Mek1DD) which promotes the sustained activation of ERK1/2 (Ishii et al., 
2014; Sheean et al., 2014). Pearson’s correlation analysis between the two gene lists showed a striking 
correlation, with a coefficient r = 0.8 between Mek1DD and Nrg1t3 and r = 0.78 between Mek1DD 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/386748doi: bioRxiv preprint first posted online Aug. 7, 2018; 
10  
and Nrg1t3;Q215X (Fig. 5B). No correlation was found between Q215X and Mek1DD (Fig. 5B), 
indicating no contribution of the P0 mutant protein itself to the regulation of MEK1-ERK pathway.  
 We further confirmed the activation of ERK-related genes downstream of NRG1 type III, as 
we found a negative correlation between our subsets and the phosphatase Shp2 KO gene subset, an 
upstream regulator of ERK1/2 phosphorylation (Grossmann et al., 2009) (Fig. 5C).  
 Our transcriptomic results showed that among the known canonical pathways downstream of 
ErbB2/3/NRG1 type III, the activation of MAPK/ERK is highly correlated to an increased level of 
NRG1 type III. Among the genes downstream the MAPK/ERK activation pathway we found the up-
regulation of fatty acid basic protein Pmp2 (encoded by Fabp8) and of myelin oligodendrocytes 
glycoprotein (encoded by Omg) (Fig. 5D). As furthermore, we found that none of the major myelin 
genes such as Mpz, Pmp22, Mag and Mbp as well as Egr2 were found deregulated in Nrg1t3 transgenic 
mice (Fig 5D). To summarize, our analyses revealed that the gene molecular signature downstream of 
NRG1 type III transgenic expression is very similar to the constitutive activation of MAPK/ERK 
pathway. Altogether these results suggest that axonal HA-NRG1 type III expression stimulates myelin 
growth in an ERK dependent manner, and activates myelin genes such as Pmp2 and Omg (Mikol et 
al., 1990; Zenker et al., 2014).  
 
MAPK/ERK constitutive activation in Schwann cells increases myelination in a model of 
congenital hypomyelination.  
Our data indicated that the ERK pathway is triggered downstream of the exogenous expression of HA-
NRG1 type III. Therefore, we assessed whether the Schwann cell specific activation of the 
MAPK/ERK pathway could also restore myelin functionality in the Q215X neuropathic context. The 
expression of a constitutively activated form of MEK1 was restricted to Schwann cells by breeding 
transgenic mice hemizygous for Mek1DD (Ishii et al., 2013) with P0-Cre mice (Mek1DD;P0Cre). 
Morphological and ultrastructure analyses from cross sections of sciatic nerves of one-month old 
animals showed a strong increase in myelin thickness in Mek1DD;P0Cre;Q215X sciatic nerves, with 
a g-ratio of 0.39±0.002 in Mek1DD;P0-Cre (Fig. 6A, B), which is even lower than Nrg1t3;Q215X 
animals (Fig. 2B). Similarly to Nrg1t3 sciatic nerves, we observed that small caliber axons were 
predominantly hypermyelinated with Mek1DD;P0Cre, and present numerous small caliber myelinated 
axons (Fig. 6C and Fig. EV4). Also, no defect in myelin compaction were observed in Mek1DD;P0Cre 
mutants at one month (Fig. 6F-G).  
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 Surprisingly, nerve conduction velocities were significantly reduced in Mek1DD;P0Cre 
mutants (Fig. 6D), and the distal amplitude of Mek1DD;P0Cre;Q215X were reduced, suggesting an 
axonal loss (Fig. 6E). Overall, MAPK/ERK pathway activation seems to have contrasting effects 
depending on its mode of activation. Beneficial effect on myelination were seen downstream of HA-
NRG1 type III transgenic expression, while the direct constitutive activation of MAPK/ERK pathway 
showed increased myelin thickness with detrimental effect on myelin functionality. 
 
HA-Nrg1 type III expression promotes changes in myelin composition  
Similarly to the constitutive activation of MEK1 (Mek1DD;P0Cre or Mek1DD;Egr2Cre) (Sheean et 
al., 2014), the transgenic expression of HA-NRG1 type III increased myelin thickness independent of 
the major myelin gene transcription factor EGR2 and of myelin protein synthesis (Fig. 5D and Fig. 
7A). However, among the genes correlated to MAPK/ERK activation pathway, we found increased 
levels of Pmp2 transcript and protein (Fig. 7A, Fig. EV5A, B), a myelin protein with functions in lipid 
homeostasis in myelinated Schwann cells (Zenker et al., 2014). As in several previous studies 
(Gillespie et al., 1990; Kadlubowski et al., 1984; Trapp et al., 1979; Zenker et al., 2014), we observed 
that cellular expression of PMP2 in wild type cross sections of sciatic nerve was found in compact 
myelin but also had cytoplasmic expression with a mosaic distribution between fibers (Fig. EV5B). In 
the presence of HA-NRG1 type III transgenic expression, PMP2 level was clearly increased while 
maintaining its mosaic distribution in sciatic nerve cross section at one month (Fig. EV5B). The 
specific increase in PMP2 suggests that NRG1 type III overexpression may determine a change in 
myelin protein composition.  
In conclusion, both elevated NRG1 type III expression and MEK1 activation increase ERK 
phosphorylation but have different outcomes on myelin structure. The activation of MAPK/ERK 
pathway results in hypermyelination associated to nerve conduction velocity deficits (Fig. 6D) and its 
prolonged activation results in the formation of aberrant myelin structure i.e misfolded myelin 
structures increasing with age, onion bulbs, compressed axons (Ishii et al., 2016; Sheean et al., 2014). 
On the contrary, sustained HA-NRG1 type III transgenic expression for one year did not alter nerve 
physiology, and we did not observe any abnormal myelin structure (Fig. 2D, Fig. 7B), as previously 
reported (Michailov et al., 2004; Velanac et al., 2012). 
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Discussion 
 
In this study, we explored a suitable treatment for a severe early-onset Charcot Marie Tooth disease 
subtype, Congenital Hypomyelinating Neuropathy. We developed and characterized a novel mouse 
model of CHN, associated with a truncation of P0 cytoplasmic tail (P0Q215X) (Fratta et al., 2018). We 
showed that animals harboring the Q215X mutation present decreased expression of major myelin 
genes and proteins and displayed the hypomyelinating features of a human CHN.  
In the peripheral nervous system, extrinsic signals from axonal neuregulin 1 type III regulate 
Schwann cell fate and myelination (Taveggia et al., 2005). Thus, the modulation of neuregulin 1 
signaling is considered as a possible approach for the restoration of myelination defects in myelin 
diseases (Bolino et al., 2016; Fledrich et al., 2014). NRG1 type III promotes myelination by stimulating 
several signaling pathways, including PI3K/AKT, calcineurin/NFATc4 and MAPK/ERK, which are 
thought to converge on the activation of EGR2 (Fig. 8). These pathways are tightly regulated. 
PI3K/AKT or MAPK/ERK pathways are both necessary for myelin protein expression (Domenech-
Estevez et al., 2016; He et al., 2010; Napoli et al., 2012) and imbalances in PI3K/AKT and MAPK/ERK 
pathways have been reported in two different demyelinating neuropathies, Charcot-Marie-Tooth type 
1A (Fledrich et al., 2014; Martini, 2014) and type 1X (Groh et al., 2015). Conversely, sustained 
activation of either PI3K/AKT or MAPK/ERK pathways leads to hypermyelination in part through the 
enhancement of protein synthesis (Domenech-Estevez et al., 2016; Ishii et al., 2016; Sheean et al., 
2014).  
Here, we show that in two different mouse models of hypomyelinated diseases i.e. congenital 
hypomyelinating neuropathy (this paper) and CMT1B (see accompanying paper by Scapin et al.), no 
initial alteration in PI3K/AKT and MAPK/ERK levels or activation was observed. Therefore, we 
expected that expression of exogenous NRG1 type III could improve functional outcomes in these 
pathologies. Indeed, we obtained the first evidences that in a CHN animal model, overexpression of 
NRG1 type III leads to increased activation of both PI3K/AKT and MAPK/ERK pathways, triggered 
the expression of genes restricted to the MAPK/ERK pathway and increases myelin thickness. We then 
showed that the sustained activation of MEK1-ERK in Schwann cell promotes an even stronger 
increase in myelin thickness, but accompanied by an alteration in nerve conduction velocity in both 
normal (as suggested in previous studies (Ishii et al., 2016; Sheean et al., 2014) and pathologic contexts, 
providing further evidences for the contrasting effect of ERK phosphorylation depending on its level 
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of expression (Ishii et al., 2016). Finally, while NRG1 type III overexpression and MEK1-ERK 
sustained activation increased myelin thickness, both were uncoupled from increased expression of 
EGR2 or major myelin genes and proteins. 
Through a comprehensive transcriptomic analysis of signaling downstream of neuregulin 1 type 
III in the context of neuropathy, we documented that in NRG1 type III overexpressing nerves, genes 
regulated by the MAPK/ERK pathway were upregulated and may contribute to increased myelin 
thickness in Schwann cells. Among these genes we identified, Pmp2, encoding for the peripheral 
myelin protein 2 and Omg, encoding for the oligodendrocyte myelin glycoprotein (OMG). Pmp2 is 
expressed in myelinating cells (Patzig et al., 2011), but only some myelinated fibers appear to maintain 
PMP2 (Trapp et al., 1979; Zenker et al., 2014). PMP2 seems to have a role in lipid homeostasis of 
myelinating Schwann cells, with recent evidences that PMP2 binds fatty acids (Majava et al., 2010; 
Zenker et al., 2014). This is particularly interesting as NRG1 was also identified upstream of MAF, a 
regulator of cholesterol biosynthesis (Kim et al., 2018), and in mice overexpressing NRG1 type III, 
cholesterol along with saturated and unsaturated fatty acids are increased (see accompanying paper 
Scapin et al.). On the other hand, there are conflicting reports on the expression of OMG in Schwann 
cells (Apostolski et al., 1994; Chang et al., 2010; Huang et al., 2005), and the function of OMG is 
unknown. Total knockout mice revealed that both PMP2 and OMG are dispensable to the formation or 
maintenance of myelin structure in the peripheral and central nervous system, respectively (Chang et 
al., 2010; Zenker et al., 2014). However, two recent studies in human revealed that de novo dominant 
mutations in PMP2 were identified in families with type 1 Charcot Marie Tooth demyelinated disease 
(Gonzaga-Jauregui et al., 2015; Motley et al., 2016). Thus, it has been suggested that mutations in 
PMP2 result to a probable toxic gain of function in myelinating Schwann cells causing demyelination 
(Gonzaga-Jauregui et al., 2015; Motley et al., 2016). Here, the hyperactivation of the MAPK/ERK 
pathway in Nrg1t3 animals appears to stimulate specifically the transcription of these less studied 
myelin proteins. The understanding of PMP2 and OMG function in Nrg1t3 animals could help us to 
understand further the mechanisms that drive hypermyelination. 
MAPK/ERK activation has been shown to have beneficial promyelinating function during 
normal development (Grossmann et al., 2009; Newbern et al., 2011; Shin et al., 2014) and to promote 
remyelination after injury (Napoli et al., 2012). Paradoxically, the activation of MAPK/ERK in 
Schwann cells has been also associated to detrimental effects on Schwann cell survival, development, 
myelination, remyelination (Maurel and Salzer, 2000; Napoli et al., 2012; Ogata et al., 2004; Syed et 
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al., 2010) and axonal regeneration (Cervellini et al., 2018).  The discrepancies between these studies 
could be explained in part by the context, the timing and the level of MAPK/ERK activation. A limited 
activation of MAPK/ERK, as in Nrg1t3 mice, was not associated to myelin structural or functional 
alterations, in accordance with previous histological examination in Nrg1t3 sciatic nerve (Michailov et 
al., 2004; Velanac et al., 2012). However, we and others showed that a sustained activation of MEK1 
is associated to aberrant myelin structures and affects axon and myelin integrity (Ishii et al., 2016; 
Sheean et al., 2014). Interestingly, we noticed that a strong decrease of EGR2 protein level specifically 
correlated with the sustained activation of MEK1 in Schwann cells, suggesting a dose effect of ERK 
phosphorylation levels on the regulation of EGR2 expression. 
 It is possible that in Nrg1t3 nerves other molecular mechanisms downstream of NRG1 type III 
limit MAPK/ERK activation over time, in contrast to the constitutively activated MAPK/ERK 
pathway. For example, we found a decreased activation of genes with NFATc4 motifs, while the total 
amount and the active (nuclear) form of NFATc4 were unchanged. In addition, we saw an upregulation 
of the PI3K/AKT pathway, which might be important to balance MAPK/ERK signaling, as suggested 
previously (Fledrich et al., 2014). Also, possible upstream mechanisms such as laminin and laminin 
receptors can limit NRG1 type III effect on myelination (Ghidinelli et al., 2017; Heller et al., 2014; 
Mogha et al., 2016; Monk et al., 2015). 
 Independently of the mechanism, we show that exogenous expression of HA-NRG1 type III 
has no detrimental effects on peripheral myelination and improved myelin thickness and nerve 
conduction velocity in both CHN and CMT1B (see accompanying paper Scapin et al.). Thus, our 
observations suggest that controlled activation of NRG1 type III could represent a favorable therapeutic 
approach in several human peripheral neuropathies associated with hypomyelination. During Schwann 
cell myelination, NRG1 type III activity is tightly regulated by complex and stepwise proteolytic 
cleavages by BACE1, TACE, GPR44 and I-CLips (Fleck et al., 2016; Hu et al., 2006; La Marca et al., 
2011; Trimarco et al., 2014; Willem et al., 2006). It is therefore possible to regulate the activity of 
specific proteases to favor the cleavage products of NRG1 type III beneficial for myelination. By this 
principle, inhibition of TACE improved myelination in an hypermyelinating model CMT4B showing 
that modulation of NRG1 type III signalling in both directions can be beneficial in different CMT 
neuropathies (Bolino et al., 2016). However, the modulation of a single protease in vivo can be 
challenging because inhibition of these proteases in regions other than peripheral nerves could have 
unwanted corollary effects; for example, TACE inhibition might promote amyloid production in the 
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brain, and sustained activation of MAPK/ERK in non-myelinating Schwann cells promotes corneal 
neurofibromas (Bargagna-Mohan et al., 2017). Finally, NRG1 type III is expressed in neurons of the 
central nervous system and exogenous expression of HA-NRG1 type III induces hypermyelination in 
the corpus callosum (Brinkmann et al., 2008; Taveggia et al., 2008). The consequences of this increase 
in myelination in the brain have not been fully investigated, but several studies have linked the increase 
of NRG1 type III to schizophrenia, possibly by disrupting cortical neuronal synaptic plasticity, and 
altering synaptic transmission (Agarwal et al., 2014; Hahn et al., 2006; Weickert et al., 2012). Thus, a 
better understanding of the function of NRG1 type III and its proteases in adult Schwann cells is 
required to manipulate NRG1 signaling specifically in the peripheral nervous system. 
 In conclusion, this study shows encouraging results for the application of NRG1 type III 
modulations in improving myelination in the context of peripheral hypomyelinated neuropathies.  
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Materials and methods  
 
Animal model. All animal experimentation was performed in strict accord with Institutional Animal 
Care and Use Committee approved protocols of San Raffaele Institute and University at Buffalo (n. 
363 and UB1188M respectively). P0Q215X knock-in mice (hereafter called Q215X) contain a targeted 
mutation in Mpz exon 5 (Fratta et al., 2018). Neuregulin 1 type III hemagglutinin-tagged transgenic 
mice (hereafter called Nrg1t3), expressing Nrg1 type III under the control of neuronal promoter Thy1.2, 
were previously described (Velanac et al., 2012). The R26StopFLMek1DD mice (hereafter called 
Mek1DD), expressing conditionally an activated form of MEK1, were previously described 
(Srinivasan et al., 2009). Mek1DD mice were cross-bred with P0-Cre transgenic mice that express Cre 
recombinase starting at E13.5 (Feltri et al., 1999; Feltri et al., 2002). We used a reporter mouse model 
containing a basal Hsp68 promoter upstream of the luciferase reporter gene activated by the +11 kb 
human PMP22 intronic enhancer containing a combinatorial Egr2/Sox10 binding site, transgenic 
luciferase line D (hereafter called Luc D) (Jones et al., 2011). 
 Q215X and P0-Cre mice were in FVB/N congenic background. Nrg1t3 and Mek1DD mice 
were in C57BL/6 background. F1 mice were respectively generated by crossbreeding Q215X mice 
with the transgenic Nrg1t3 mice and Q215X with Mek1DD in C57BL/6xFVB/N mixed background. 
Luciferase mice were in mixed background C57BL/6xFVB/N/CBA. Genotyping of mutant P0-Cre, 
Nrg1t3 and Mek1DD mice was performed by PCR on tail genomic DNA, as described previously 
(Feltri et al., 1999; Jones et al., 2011; Michailov et al., 2004; Srinivasan et al., 2009).  The genotype of 
Q215X animals was determined by PCR analysis with Mpz forward primer: 5′-
CAACCTCTCTTGCCACAGTG-3′ and Mpz reverse primer: 5′-GCTAACCGCTATTTCTTATCC-3′ 
which amplified 400 and 280 nucleotide fragments, for Q215X and wild type allele respectively. PCR 
conditions were: 94 °C for 1 minute (min), 56 °C for 1 min and 72 °C for 1 min (29 cycles), followed 
by 10 min extension at 72 °C, in a standard PCR reaction mix.  
No animals were excluded from the study. Animals were housed in cages of no more than 5 
animals in 12 h light / dark cycles. Mutant and control littermates from either sex were sacrificed at the 
indicated ages, and sciatic nerves were dissected.  
 
Functional analyses. Grid walking test was used to measure the frequency of step errors on rungs 
of an elevated grid. Littermate mice were allowed to walk on a mesh grid for 5 trials of 5 min each, 
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with the first three trials considered as training period. Hindpaw placement errors (Foot faults) defined 
as passage of the hindpaw through an opening in the grid were determined as a proportion of total 
hindpaw steps on horizontal grid mesh (1.2 × 1.2 cm openings). Sciatic nerve motor conduction 
velocity and amplitude were obtained as previously described (Poitelon et al., 2015; Poitelon et al., 
2016). 
 
Morphology. Semithin section and electron microscopic analyses of sciatic nerves were performed 
as previously described (Quattrini et al., 1996). For g-ratio (axon diameter/fiber diameter) and axonal 
distribution, four semithin images per sciatic nerve were acquired with the 100X objective. Three to 
four animals per age per genotype were analyzed. Axon and fiber diameters were quantified using the 
Leica QWin software (Leica Microsystem). Data were analyzed using GraphPad Prism 6.01. 
Periodicity was measured at 20,000X magnification as previously described (Wrabetz et al., 2006). 
Immuno-electron microscopy was performed as in (Quattrini et al., 1996) but with embedding modified 
as described (Yin et al., 2000). Primary antibody was chicken anti-P0 (Aves). Gold-conjugated 
secondary antibodies were 10 nM for P0 (British Biocell International). For teased fibers, sciatic nerves 
were fixed in 2 % glutaraldehyde overnight at 4 °C, washed 3 times in phosphate buffer (79 mM 
Na2HPO4, 21 mM NaH2PO4, pH 7.4). Sciatic nerves were stained in 1 % osmium, washed 4 times in 
phosphate buffer and incubated at 55 °C for twelve hours (h) in 30 % glycerol followed by 12 h in 60 
% glycerol and 12 h in 100 % glycerol. 
 
Western analysis. Sciatic nerves were dissected, frozen in liquid nitrogen, pulverized and 
resuspended in lysis buffer (150 mM NaCl, 25 mM HEPES, 0.3 % CHAPS pH 7.4, 1 mM Na3VO4, 1 
mM NaF and 1:100 Protease Inhibitor Cocktail (Roche). Protein lysates were centrifuged at 13000 g 
for 20 min at 4°C. Supernatant protein concentrations were determined by BCA protein assay (Thermo 
Scientific) according to the manufacturer’s instructions. Equal amounts of homogenates were diluted 
3:1 in 4X Laemmli (250 mM Tris-HCl pH 6.8, 8 % SDS, 8 % β-Mercaptoethanol, 40 % Glycerol, 0.02 
% Bromophenol Blue), denatured 5 min at 100 °C, resolved on SDS-polyacrylamide gel, and 
electroblotted onto PVDF membrane. Blots were then blocked with 5 % BSA in 1X PBS, 0.05 % 
Tween-20 and incubated over night with the appropriate antibody. Cell Signalling anti-AKT (9272) 
1/1,000, anti-p-AKT Ser473 (9271) 1/1,000, anti-p-AKT Thr308 (5106) 1/1000, anti-ERK 1/2 (#9102) 
1/1,000, anti-p-ERK 1/2 p44/42 (9101) 1/1,000, anti-NFATc4 (2183) 1/1000. Aves anti-P0 (PZO) 
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1/5000. Covance anti-MBP (SMI94) 1/1000, anti-TUJ1 (MMS-435P) 1/5000. Sigma anti-GAPDH 
(G9545) 1/2000, anti-Calnexin (C4731) 1/3000. Santa Cruz anti-PMP2 (sc-374058), anti-HSP90 (sc-
7947) 1/1000. Abcam anti-PMP22 (ab15506) 1/1000, anti-ErbB2 (ab2428) 1/200 and anti p-ErbB2 
Y1248 (ab47755) 1/1000. Invitrogen anti-MAG (34-6200) 1/1000. Roche anti-HA (11867423001) 
1/200. anti-EGR2 1/200 was gifted by Dr. Meijer, Centre for Neuroregeneration, Edinburgh. 
Membranes were then rinsed in 1X PBS and incubated for 1h with secondary antibodies. Blots were 
developed using ECL, ECL plus (GE Healthcare) or Odyssey CLx infrared imaging system (Li-Cor). 
Western blots were quantified using Image J software (http://imagej.nih.gov/ij). Each experiment was 
performed at least two times on nerves from at least three animals. 
 
Immunofluorescence and immunohistochemistry. For immunohistochemistry, sciatic nerves 
were fixed with 4 % PFA and embedded in OCT. Cross sections were permeabilized with cold MetOH. 
Sections were rinsed in 1X PBS, blocked for 1 h in 20 % fetal bovine serum, 2 % BSA, 0.1 % Triton 
X-100 in 1X PBS. The following primary antibodies were incubated overnight: Proteintech anti-PMP2 
(12717-AP) 1/500, Aves Labs anti-P0 (PZO) 1/1000. Sections were rinsed in 1X PBS, incubated 1 h 
with Jackson TRITC-conjugated (711-025-152) 1/200 and with Jackson DyLight 488 1/1,000, stained 
with DAPI, and mounted with Vectashield (Vector Laboratories). Images were acquired with a Zeiss 
ApoTome. 
 
RNA extraction and quantitative RT-PCR. Total RNA was extracted from sciatic nerves using 
TRIzol® (Life Technologies). Several pools of nerves of two to six nerves were used depending the 
animal age. For RT-QPCR analysis, first strand cDNA was synthesized from 1 µg total RNA using 
polythymine and random primers with Superscript III RNAse H reverse transcriptase (Invitrogen). The 
expression of selected mRNAs was determined by quantitative real-time PCR using 20 ng of cDNA. 
Samples were processed in triplicate and reactions without target cDNA were used as negative control 
for each reaction. PCRs were performed on 96-well plates using the Power SYBR Green PCR Master 
Mix (Applied Biosystems), Taqman probe assays or FastStart Universal Probe Master (Roche 
Diagnostic) following manufacturer’s conditions.  Data were analyzed using the threshold cycle (Ct) 
and 2(-ΔΔCt) method. Actb, Hsp90, Gapdh or Pgk1 genes were used as reference for normalizing the 
data. The Taqman probes used are the following: Actb (Mm00607939-S1), Gapdh (Mm99999915-g1), 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/386748doi: bioRxiv preprint first posted online Aug. 7, 2018; 
19  
Pgk1 (Mm00435617), Pmp2 (Mm03015237_m1), Mpz (Mm00485139-m1), Mbp (Mm01262035), 
Mag (Mm00487541-m1), Egr2 (Mm00456650-m1), Pmp22 (Mm01333393_m1). 
 
RNAseq analysis. Sciatic nerves at P30 were dissected, frozen in liquid nitrogen and pulverized. 
Total RNA was prepared from pools of two nerves with TRIzol (Roche Diagnostic), then purified with 
RNeasy column (Qiagen). Samples were quantified using Ribogreen Assay (Invitrogen) and the quality 
of samples was checked using Agilent Bioanalyzer 2100 RNA nano 6000 chip (Agilent). Illumina 
TruSeq RNA sample preparation kit (Illumina) was used to prepare cDNA libraries from RNA samples. 
Samples were poly A selected to isolate mRNA, the mRNA was cleaved into fragments, the first strand 
reverse transcribed to cDNA using SuperScript II reverse Transcriptase (Invitrogen) and random 
primers, followed by second strand cDNA synthesis using Second Strand Master Mix supplied with 
the kit. After end repair, the addition of a single ‘A’ base, and ligation with adapters, the products were 
enriched and purified with PCR to create the final cDNA library as per manufacturer’s protocol. cDNA 
libraries were quantified using Picogreen Assay (Invitrogen) and Library Quantification kit (Kapa 
Biosystems). Agilent Bioanalyzer 2100 DNA 7500 chip was used to confirm the quality and size of 
the cDNA libraries. The cDNA libraries were then normalized, pooled and paired-end sequenced (100 
standard cycles) using the Illumina HiSeq2500 following the manufacturer’s instructions at the UB 
Genomics and Bioinformatics Core Facility (Buffalo, NY). Reads were aligned to the mouse reference 
genome (mm10) with the transcript annotation (UCSC mm10 annotation download from TopHat 
website) using TopHat (v2.0.9). Quantification for the gene expression and differential expression 
analysis were done using the Cufflinks software (v2.2.0). Data are available at 
http://www.ncbi.nlm.nih.gov/geo/ accession number: GSE101808.  
 
Experimental Design. Experiments were not randomized, but data collection and analysis were 
performed blindly to the conditions of the experiments. Researchers blinded to the genotype performed 
behavioral analyses, nerve conduction velocities and morphometric analyses. This study was not 
preregistered. Most experiments were conducted with 3 animals per age and per genotype. No 
statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those 
generally employed in the field.  
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Statistical analyses. The data obtained are presented in mean ± s.e.m. One-way ANOVA with 
Bonferroni’s comparison test was used for statistical analysis of the differences among multiples 
groups. Values of P < 0.05 were considered to represent a significant difference.  
Each Pearson’s correlation coefficient (r) was calculated from sets of genes selected with a fold change 
cutoff ≥ 1.2. Correlation plots show the linear relationship between gene sets obtained from P30 sciatic 
nerves.  
A hypergeometric-based test (Fisher exact test) interrogated for enrichment of regulated genes from 
RNA sequencing from nerves of various genotypes, in subsets of regulated genes selected from Sox10 
ChIP-Seq (Lopez-Anido et al., 2015; Srinivasan et al., 2012) with or without NFATc4 motif 
enrichment. Motifs (MA0152.1 Jaspar) were called using the Homer annotate Peaks program with 
option -m (Heinz et al., 2010). The rationale for using the hypergeometric test was that if genes 
activated downstream of Nrg1 type III had any biological or functional association with the 
calcineurin/NFATc4 pathway, a higher number of genes would be found regulated in nerve and present 
in ChIP-Seq libraries than expected by chance.  
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The paper explained 
 
Problem: Hereditary demyelinating neuropathies are important neuromuscular disorders with 
significant social and economic impact. Among them, neuropathies due to Myelin Protein Zero (MPZ) 
mutations are relatively common and of widely varying phenotype, including Charcot Marie Tooth 1B 
(CMT1B) with onset in childhood or in adulthood, and Congenital Hypomyelination neuropathy 
(CHN) apparent at birth. There is no treatment for MPZ-neuropathies. We have produced and 
characterized a variety of mouse models for MPZ-neuropathies and showed that different mutations 
cause pathology by different mechanisms. Thus, even within MPZ-neuropathies, it may be difficult to 
identify unifying therapies that target each pathogenic mechanism. However, because hypomyelination 
and demyelination are common features of all these neuropathies, we turned to final-common pathways 
that regulate myelination. 
Results: Neuregulin 1 type III (NRG1 type III) promotes peripheral myelin formation and thickness. 
Therefore, we explored the hypothesis that augmenting NRG1 type III levels may ameliorate 
hypomyelination, demyelination and inefficient remyelinaton in a preclinical model of CHN and 
CMT1B (Scapin et al., this issue), despite different pathogenic mechanisms. 
Impact: Our paper establishes for the first time that overexpression of NRG1 type III rescues 
myelination and nerve conduction velocity in mice carrying a nonsense P0 mutation that causes CHN. 
These effects are accomplished without altering major myelin protein levels. Instead, genes regulated 
by the MAPK/ERK pathway are upregulated and may contribute to increased myelin thickness in 
Schwann cells. Together, this study and the one led by the D’Antonio lab (Scapin et al., this issue) 
provide novel results supporting that exogenous expression of NRG1 type III has no detrimental effects 
on peripheral myelination and can improve myelination in CHN and CMT1B. Thus, our observations 
suggest that controlled activation of NRG1 type III could represent a favorable therapeutic approach 
in several human peripheral neuropathies associated with hypomyelination. 
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Figure Legends 
 
Figure 1. The Q215X mutation in P0 causes hypomyelination and alters myelin genes 
expression. (A) Semithin cross-sections stained with toluidine blue from wildtype (WT), P0Q215X 
heterozygote (Q215X/+) and P0Q215X homozygote (Q215X/Q215X) sciatic nerves at 1 month. 
Q215X/+ and Q215X/Q215X fibers are hypomyelinated as compared to WT. Scale bars, 10 µm. (B) 
g-ratio was increased in Q215X mutants from 0.66±0.0005 (WT) to 0.72±0.003 (Q215X/+) and 
0.76±0.005 (Q215X/Q215X). (C-F) mRNA relative quantification by real time PCR for Pmp22, Mag, 
Mbp and Erg2 in WT, Q215X/+, Q215X/Q215X sciatic nerves at P5, P10, P15 and P30. (G-J) 
Densitometries from western blot analyses of PMP22, MAG, MBP and EGR2. Western blot analyses 
were performed on sciatic nerves lysates of WT, Q215X/+, Q215X/Q215X at P5, P10, P15 and P30. 
Representative blots are shown in Fig. EV1. Analyses were performed using three mice per genotype. 
Error bars indicate s.e.m. Statistical analyses were performed using one-way ANOVA with 
Bonferroni’s multiple comparison. * P < 0.05, ** P < 0.01, *** P < 0.001.   
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Figure 2. Neuronal overexpression of NRG1 type III restores myelination in P0Q215X. 
(A) Semithin cross-sections stained with toluidine blue (top panel) and electron micrographs (bottom 
panel) from wildtype (WT), Nrg1t3 hemizygote (Nrg1t3), P0Q215X heterozygote (Q215X) and 
Nrg1t3 hemizygote and P0Q215X heterozygote (Nrg1t3;Q215X) sciatic nerves at one month. NRG1t3 
and Nrg1t3;Q215X fibers are hypermyelinated as compared to WT and Q215X. Scale bars, 10 µm (top 
panel) and 2 µm (bottom panel). (B) g-ratio was increased in Q215X (0.72±0.003) and decreased in 
Nrg1t3 (0.53±0.02), indicating hypomyelination and hypermyelination, respectively. (C) g-ratio as a 
function of axonal diameter showed preferential hypermyelination of small fibers in Nrg1t3 and 
Nrg1t3;Q215X as compared to WT and Q215X. (D) Neurophysiological studies showed a significant 
reduction of nerve conduction velocity in Q215X mice when compared to WT (47.28±0.97 m/s). A 
recovery of nerve conduction velocities can be observed in Nrg1t3;Q215X (39±1.5 m/s) as compared 
to Q215X (35±1.28 m/s) (P = 0.06). (E) F wave latencies were increased in Q215X (6.54±0.11 m/s) 
when compared to WT (5.32±0.08 m/s). A significant recovery of F wave latencies is observed in 
Nrg1t3;Q215X (6±0.12 m/s), suggesting a proximal myelination improvement. (F-G) Myelin 
compaction is not altered in single or double mutant as indicated in electron micrographs (F) and 
periodicity quantification (G). Scale bar, 50 nm. Analyses were performed using three mice per 
genotype. Error bars indicate s.e.m. Statistical analyses from three independent experiments using one-
way ANOVA with Bonferroni’s multiple comparison test. ** P < 0.01, *** P < 0.001. 
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Figure 3. Expression of HA-NRG1 type III does not affect myelin gene expression. (A) 
Densitometries from western blot analyses of P0, PMP22, MAG and MBP performed from WT, 
Nrg1t3, Q215X and Nrg1t3;Q215X sciatic nerves lysates at one month of age. Protein levels remain 
steady in all genotypes. Representative blots are shown in Fig. EV3C. (B) Immunogold labeling of P0 
protein from cross sections of WT, Nrg1t3, Q215X and Nrg1t3;Q215X sciatic nerves at one month. 
Quantification of gold particles associated with P0 from cross sections of sciatic nerve at P30. Scale 
bar, 200 nm (C) Relative quantification of mRNA for Mpz, Pmp22, Mag and Mbp in WT, NRG1t3, 
Q215X, NRG1t3;Q215X sciatic nerves at one month. Analyses were performed using three mice per 
genotype. Error bars indicate s.e.m. Statistical analyses were performed using one-way ANOVA with 
Bonferroni’s Multiple comparison test. * P < 0.05, ** P < 0.01, *** P<0.001. 
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Figure 4. Expression of HA-NRG1 type III triggers the activation of ERK and AKT. 
Densitometries and western bot analyses of (A) P-AKT, AKT, (B) P-ERK, ERK, (C) P-NFATc4 and 
NFATc4 were performed on WT, Nrg1t3, Q215X and Nrg1t3;Q215X sciatic nerves lysates at one 
month. Increased activation of AKT and ERK was observed in NRG1t3 and Nrg1t3;Q215X. NFATc4 
activation level was unchanged. Western blots were cropped. Analyses were performed using three 
mice per genotype. Error bars indicate s.e.m. Statistical analyses were performed using one-way 
ANOVA with Bonferroni’s Multiple comparison test. * P < 0.05, ** P < 0.01, *** P<0.001. 
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Figure 5. Transcriptomic signature in Nrg1t3 sciatic nerves correlates with the signature 
of activation of the MAPK/ERK pathway. (A-C) Pearson’s correlation between RNA deep 
sequencing from one-month old sciatic nerve of NRG1t3 (left panel in blue), Q215X (middle panel in 
red) and Nrg1t3;Q215X (right panel in purple) and targets downstream of EGR2 and ERK. (A) 
Pearson’s correlation analysis with combined ChIP-Sequencing and arrays data sets obtained from 
mice homozygous for an Egr2 hypomorphic allele (Egr2lo/lo). Pair-wise correlation analysis showed no 
correlation between the exogenous expression of Nrg1t3 and EGR2 downstream regulated genes. (B) 
Pearson’s correlation analysis with arrays data sets obtained from conditional Schwann-specific 
constitutive active form of MEK1 (Mek1DD;Egr2Cre), that phosphorylates ERK. Pair-wise correlation 
showed a high correlation between the exogenous expression of NRG1 type III and MEK1 downstream 
regulated genes (Panel B blue and purple). (C) Pearson’s correlation analysis with arrays data set 
generated from Schwann cell conditional knockout for Shp2 (Egr2Cre), which dephosphorylates ERK. 
Paired-wise correlation showed an anticorrelation between exogenous expression of HA-NRG1 type 
III and Shp2 loss of function (panel C blue and purple). (D) Fold change of transcripts for neuregulin 
1, transcription factors regulating myelination and myelin genes obtained from mRNA deep 
sequencing in Nrg1t3, Q215X and Nrg1t3;Q215X in one-month mice sciatic nerve. The quantification 
showed an overall unchanged level of the major regulators and components of the myelin, apart for 
Pmp2 (a fatty acid binding protein, Fabp8) and Omg (oligodendrocyte myelin glycoprotein). 
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Figure 6. Constitutive activation of MAPK/ERK increases peripheral myelination in 
normal and Q215X genetic context, but it is functionally detrimental. (A) Semithin cross-
sections stained with toluidine blue (top panel) and electron micrographs (bottom panel) from wildtype 
WT, Q215X, Mek1DD hemizygote and P0-Cre hemizygote (Mek1DD;P0Cre) and Mek1DD 
hemizygote, P0-Cre hemizygote and Q215X (Mek1DD;P0Cre;Q215X) sciatic nerves at one month. 
Mek1DD;P0Cre and Mek1DD;P0Cre;Q215X fibers are hypermyelinated and Q215X are 
hypomyelinated. Scale bars, 10 µm (top panel) and 2 µm (bottom panel). (B) g-ratio was increased in 
Q215X (0.70±0.008) and decreased in Mek1DD;P0Cre (0.40±0.002) and Mek1DD;P0Cre;Q215X 
(0.39±0.002) compared to WT (0.64±0.002), indicating hypomyelination and strong hypermyelination, 
respectively.  (C) g-ratio as a function of axonal diameter showed preferential hypermyelination of 
small fibers in Mek1DD;P0Cre and Mek1DD;P0Cre;Q215X. (D-E) Neurophysiological studies 
showed  significantly reduced nerve conduction velocity in all mutants (D). Note that Mek1DD;P0Cre 
animals displayed an even more dramatic reduction. (E) The amplitude of compound muscle action 
potentials was decreased in Mek1DD;P0Cre;Q215X, suggesting axonal loss. (F-G) Myelin 
compaction (F) and periodicity (G) were not altered in Mek1DD;P0Cre and Mek1DD;P0Cre;Q215X 
sciatic nerves. Scale bar, 50 nm. Analyses were performed using three mice per genotype. Error bars 
indicate s.e.m. Statistical analyses were performed using one-way ANOVA with Bonferroni’s multiple 
comparison test. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 7. Expression of HA-NRG1 type III transgene increases PMP2 protein level. (A) 
Western blot analysis from WT, Nrg1t3, Q215X, Nrg1t3;Q215X, Mek1DD;P0Cre and 
Mek1DD;P0Cre;Q215X sciatic nerves at one month. Expression of HA-NRG1t3 transgene in sciatic 
nerves or constitutive activation the MAPK/ERK pathway in Schwann cells leads to an increase in 
ERK phosphorylation, a decrease in EGR2 protein levels and an increase in PMP2 protein levels. These 
effects are enhanced in Mek1DD;P0Cre mutants as compared to HA-NRG1t3 mutants. Western blots 
were cropped. (B) Semithin cross-sections stained with toluidine blue (top panel) and electron 
micrographs (bottom panel) from wildtype (WT), Nrg1t3 hemizygote (Nrg1t3), P0Q215X 
heterozygote (Q215X) and Nrg1t3 hemizygote and P0Q215X heterozygote (Nrg1t3;Q215X) sciatic 
nerves at one year. 
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Figure 8. Regulation of myelination by NRG1 type III. In wildtype animals, NRG1 type III/ 
ErbB2/3 promotes myelination by stimulating several signaling pathways, including PI3K/AKT, 
MAPK/ERK and calcineurin (CaN)/NFATc4, which are thought to converge on the activation of 
EGR2. In Nrg1t3 animals the exogenous expression of NRG1 type III leads to the activation of both 
PI3K/AKT and MAPK/ERK pathways and the increased transcription of Pmp2 and Omg. 
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Expanded View Figure Legends 
 
Figure EV1. The P0Q215X disrupts myelin gene regulation and modifies myelin protein 
expression throughout the development. Western analysis from WT, Q215X (Q/+), 
Q215X/Q215X (Q/Q) sciatic nerves during development at P5, P10, P15 and P30 days. Blots were 
probed for P0, PMP22, MAG, MBP and EGR2. The Q215X allele cause a reduction of P0 stability 
(Fratta et al., 2018). Calnexin was used as loading control. Analyses were performed using three mice 
per genotype. Western blots were cropped. 
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Figure EV2. Expression of HA-NRG1 type III promotes a shift in the size of myelinated 
fiber population and an increase in internodal length. (A) The distribution of myelinated fibers 
shows a larger population of small myelinated axon (axon diameter from 1 to 2 um) in Nrg1t3 compare 
to WT. (B-C) While no reduction in internodal lengths was measured in the Q215X, the internodal 
lengths were increased in both Nrg1t3 and Nrg1t3;Q215X and Nrg1t3 by approximately 15% (B). At 
least 100 internodes were measured (C). Scale bar 100 µm. Analyses were performed using three mice 
per genotype. Error bars indicate s.e.m. Statistical analyses were performed using one-way ANOVA 
with Bonferroni’s multiple comparison test. * P < 0.05. 
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Figure EV3. The hypermyelination mediated by HA-NRG1 type III transgenic expression 
does not correlates with an increase in major myelin components or in EGR2 activation. 
(A) Western blot analyses from WT, Q215X, Nrg1t3;Q215X and Nrg1t3 spinal cord at P30. Blots were 
probed for HA tag. HA is tagged to the NRG1 type III transgene. Calnexin was used as loading control. 
We detected exogenous neuregulin precursor protein level and its cleavage products. The upper band 
corresponds to the full-length NRG1 type III inactive isoform (135-kDa, arrow), the 75-kDa band 
corresponds to the active form (arrow head) of NRG1 type III produced by BACE1-cleavage, as 
described in the literature (La Marca et al., 2011; Velanac et al., 2012). (B-D) Western blot analyses 
from WT, Q215X, Nrg1t3;Q215X and Nrg1t3 sciatic nerves at P30. Blots were probed for P-ErbB2, 
ErbB2 (B), P0, MBP, PMP22, MAG (C) and EGR2 (D). HSP90 was used as loading control. (E) 
Relative quantification of Egr2 mRNA from WT, Nrg1t3, Q215X, HA-Nrg1t3;Q215X sciatic nerves 
at P30. (F) Relative quantification of luciferase reporter gene mRNA (Lucif) from Luc D hemizygotes 
(Luc D), Q215X;LucD, Nrg1t3;Luc D and Nrg1t3;Q215X;LucD sciatic nerves at P15. Luc D mice 
harbor a combinatorial EGR2/SOX10 binding site upstream of basal Hsp68 promoter. No significant 
differences were found at P15. Analyses were performed using three mice per genotype. Error bars 
indicate s.e.m. Statistical analyses were performed using one-way ANOVA with Bonferroni’s multiple 
comparison test. *** P < 0.001. 
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Figure EV4. Mek1DD;P0Cre transgene promotes a shift in the size of myelinated fiber 
population. The distribution of myelinated fibers shows a larger population of small myelinated axon 
(axon diameter from 1 to 2 um) in Mek1DD;P0Cre and Mek1DD;P0Cre;Q215X as compared to WT 
and Q215X at one month. Analyses were performed using three mice per genotype. Western blot were 
cropped. Statistical analyses were performed using one-way ANOVA with Bonferroni’s multiple 
comparison test. * P < 0.01, *** P < 0.001. 
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Figure EV5. Expression of HA-NRG1 type III increases Pmp2 mRNA and protein levels. 
(A) Relative quantification of Pmp2 mRNA from WT, Nrg1t3, Q215X, Nrg1t3;Q215X sciatic nerves 
at one month. There is a significant up regulation of Pmp2 (1.89 ± 0.16 folds in NRG1t3 and 1.81 ± 
0.15 in Nrg1t3;Q215X). Error bars indicate s.e.m. Analyses were performed using three mice per 
genotype. Statistical analyses were performed using one-way ANOVA with Bonferroni’s multiple 
comparison test. *** P < 0.001. * P < 0.05. (B) Immunolabelling for PMP2 (in red) and P0 (in green) 
in cross-section from WT, Nrg1t3, Q215X, Nrg1t3;Q215X sciatic nerves at one month. PMP2 staining 
is increased in Nrg1t3 and Nrg1t3;Q215X  sciatic nerves. Scale bar, 25µm.  
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